PubRank

Nikhil C Munshi

Author PubWeight™ 253.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Signatures of mutational processes in human cancer. Nature 2013 21.63
2 Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 4.52
3 Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002 4.33
4 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011 4.00
5 Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010 4.00
6 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 3.89
7 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2002 3.73
8 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2002 3.62
9 CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009 3.37
10 Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009 3.21
11 Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009 3.12
12 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006 3.04
13 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002 3.01
14 Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002 2.83
15 Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002 2.66
16 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2007 2.65
17 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009 2.61
18 Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009 2.59
19 Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006 2.32
20 Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012 2.29
21 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006 2.24
22 Antimyeloma activity of heat shock protein-90 inhibition. Blood 2005 2.24
23 Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003 2.23
24 Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2003 2.22
25 Focus on multiple myeloma. Cancer Cell 2004 2.10
26 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011 2.07
27 The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006 1.98
28 Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011 1.97
29 Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003 1.92
30 Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009 1.92
31 Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2012 1.91
32 Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 2008 1.85
33 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005 1.84
34 Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004 1.82
35 Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood 2012 1.81
36 Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005 1.79
37 Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 2008 1.79
38 MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013 1.79
39 Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010 1.79
40 Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2008 1.76
41 Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013 1.75
42 PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010 1.75
43 Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010 1.73
44 Dysfunctional T regulatory cells in multiple myeloma. Blood 2005 1.72
45 Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 2003 1.66
46 Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011 1.66
47 Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007 1.65
48 Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002 1.64
49 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2006 1.63
50 Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006 1.62
51 A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005 1.60
52 Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007 1.60
53 MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008 1.59
54 Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010 1.58
55 Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 2012 1.54
56 Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009 1.54
57 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003 1.53
58 Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012 1.50
59 A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014 1.47
60 Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002 1.45
61 High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007 1.45
62 Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006 1.45
63 Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013 1.44
64 Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005 1.42
65 Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004 1.42
66 Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007 1.41
67 Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009 1.41
68 p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004 1.38
69 Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003 1.34
70 Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 2005 1.32
71 Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004 1.31
72 In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004 1.31
73 Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007 1.30
74 Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003 1.28
75 The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007 1.26
76 Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004 1.26
77 Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther 2003 1.26
78 Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005 1.24
79 Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013 1.23
80 Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006 1.21
81 Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004 1.21
82 A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009 1.20
83 Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2002 1.18
84 The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 2009 1.18
85 A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 2010 1.18
86 Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2012 1.14
87 Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc 2007 1.14
88 In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008 1.13
89 Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002 1.11
90 Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008 1.11
91 Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004 1.10
92 Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009 1.09
93 Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005 1.09
94 Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2003 1.09
95 Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011 1.07
96 Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012 1.07
97 Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res 2008 1.04
98 The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002 1.04
99 Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003 1.03
100 CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2002 1.03
101 Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 2012 1.03
102 Retracted CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009 1.01
103 Minimal residual disease in multiple myeloma. J Clin Oncol 2013 1.01
104 Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 2008 1.01
105 Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol 2007 1.00
106 Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 2009 1.00
107 Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009 1.00
108 Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009 1.00
109 Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011 0.98
110 Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2008 0.97
111 A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004 0.97
112 Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012 0.96
113 Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol 2003 0.96
114 Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007 0.95
115 canEvolve: a web portal for integrative oncogenomics. PLoS One 2013 0.95
116 Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005 0.95
117 Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol 2013 0.95
118 SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 2005 0.95
119 High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009 0.94
120 A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol 2012 0.93
121 A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 2014 0.93
122 Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res 2004 0.93
123 Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009 0.93
124 Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res 2011 0.93
125 The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol 2012 0.91
126 Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 2005 0.91
127 Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park) 2010 0.91
128 Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood 2012 0.91
129 Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol 2011 0.90
130 Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A 2012 0.90
131 CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008 0.89
132 In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009 0.89
133 Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol 2010 0.86
134 Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents 2002 0.86
135 Phase transitions in human IgG solutions. J Chem Phys 2013 0.85
136 Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011 0.85
137 Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. Cancer Res 2002 0.84
138 Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood 2006 0.84
139 Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res 2003 0.83
140 A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood 2005 0.83
141 A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011 0.83
142 Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol 2014 0.82
143 In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol 2006 0.82
144 The shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics 2013 0.82
145 Multicentric plasma cell variant of Castleman's disease with cutaneous involvement. J Cutan Pathol 2004 0.82
146 Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma 2011 0.82
147 Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res 2013 0.81
148 Individualized therapy in multiple myeloma: are we there? Semin Oncol 2013 0.81
149 Immune therapies. Hematol Oncol Clin North Am 2007 0.81
150 Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics Proteomics 2012 0.80
151 Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program 2008 0.80
152 Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol 2007 0.80
153 MRI features of extramedullary myeloma. AJR Am J Roentgenol 2014 0.80
154 The dChip survival analysis module for microarray data. BMC Bioinformatics 2011 0.80
155 Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.79
156 A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol 2015 0.78
157 beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol 2002 0.78
158 MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood 2014 0.77
159 Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One 2013 0.77
160 MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park) 2011 0.77
161 A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 2007 0.76
162 Immunotherapy for multiple myeloma. Expert Rev Hematol 2014 0.76
163 Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol 2010 0.76
164 Interaction of adeno-associated virus Rep78 with SV40 T antigen: implications in Rep protein expression leading to the inhibition of SV40-mediated cell proliferation. Intervirology 2002 0.76
165 Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013 0.75
166 Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med 2016 0.75
167 FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol 2006 0.75
168 Integration of novel agents into treatment of myeloma. Clin Lymphoma Myeloma 2007 0.75
169 Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol 2006 0.75
170 Retracted MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 2010 0.75